ライフサイエンスコーパス: mucinous neoplasm

1 ement of patients with Intraductal Papillary Mucinous Neoplasms.

2 the mouse pancreas and prevents formation of mucinous neoplasms.

3 use pancreas to induce intraductal papillary mucinous neoplasms.

4 s on the treatment of intraductal pancreatic mucinous neoplasms.

5 adenocarcinoma, 17 had intraductal papillary mucinous neoplasms, 26 had symptomatic chronic pancreati

6 ndocrine tumors (35%), intraductal papillary mucinous neoplasms (33%), solid pseudopapillary neoplasm

7 s cystic neoplasm =16, intraductal papillary mucinous neoplasm = 5, neuroendocrine tumors = 4), or 10

8 = 4), or 10 malignant (intraductal papillary mucinous neoplasm = 7, cystadenocarcinomas = 3) lesions.

9 compared with invasive intraductal papillary mucinous neoplasm (84.5% vs. 36%; P < 0.001).

10 28, borderline 7), 22 intraductal papillary mucinous neoplasms (adenoma 9, borderline 9, cancer 4),

11 s for the treatment of intraductal papillary mucinous neoplasm and cystic lesions of the pancreas app

12 Intraductal papillary mucinous neoplasm and pancreatic neuroendocrine tumor bi

13 esection of pancreatic intraductal papillary mucinous neoplasm and to correlate recurrence and surviv

14 ntified in 85 HRIs (82 intraductal papillary mucinous neoplasms and 3 pancreatic endocrine tumors).

15 asia in less than 3 cm intraductal papillary mucinous neoplasms and in multiple intraepithelial neopl

16 ucinous cysts, such as intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, have t

17 rs, two Brenner tumors not associated with a mucinous neoplasm, and two atypical proliferative (borde

18 omas, 23 as noninvasive proliferative cystic mucinous neoplasms, and only 7 as cystadenocarcinomas.

19 us cystic neoplasm and intraductal papillary mucinous neoplasm are superior to the original 2006 guid

20 More cases of intraductal papillary mucinous neoplasms are being diagnosed and studied.

21 endocrine tumors, and intraductal pancreatic mucinous neoplasms are included.

22 Intraductal papillary mucinous neoplasms are increasingly diagnosed cystic pre

23 Intraductal papillary mucinous neoplasms are the most common pancreatic malign

24 lassified 113 resected intraductal papillary mucinous neoplasms as invasive carcinoma (n = 40) or as

25 ho underwent "curative" resection for cystic mucinous neoplasms at Mayo Clinic Rochester from 1940 to

26 (</=30 mm) branch-duct intraductal papillary mucinous neoplasm (BD IPMN; 67%), whereas also being spe

27 cially for branch duct intraductal papillary mucinous neoplasms (BD-IPMNs), remain uncertain.

28 lopment of branch duct intraductal papillary mucinous neoplasms (BD-IPMNs).

29 ology should be retained for both serous and mucinous neoplasms because of the risk of extraovarian i

30 Intraductal papillary mucinous neoplasms can be multifocal and a potential cau

31 nous cystic neoplasms, intraductal papillary mucinous neoplasm, cystic neuroendocrine tumors, and cys

32 inous cystic neoplasms+intraductal papillary mucinous neoplasms) from benign cystic lesions (serous c

33 ly one patient with an intraductal papillary mucinous neoplasm had high-grade dysplasia.

34 for the management of intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm we

35 nt of branch duct (BD) intraductal papillary mucinous neoplasm (IPMN) espouse safety of observation o

36 ic duct (MPD)-involved intraductal papillary mucinous neoplasm (IPMN) has been established by surgica

37 eatic branch-duct (BD) intraductal papillary mucinous neoplasm (IPMN) is infrequent and that extrapan

38 re similar to those of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.

39 neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) precursor lesions.

40 Human intraductal papillary mucinous neoplasm (IPMN) specimens were analyzed by immu

41 tic lesions resembling intraductal papillary mucinous neoplasm (IPMN) were observed as early as 2 mon

42 s preneoplastic lesion intraductal papillary mucinous neoplasm (IPMN), to find new microRNA (miRNA)-b

43 inoma in patients with intraductal papillary mucinous neoplasm (IPMN).

44 population of resected intraductal papillary mucinous neoplasms (IPMN) of the pancreas with respect t

45 for the management of intraductal papillary mucinous neoplasms (IPMN) recommend surgical treatment i

46 section for pancreatic intraductal papillary mucinous neoplasms (IPMN) using targeted next-generation

47 s, 2 cysts/remnants, 4 intraductal papillary mucinous neoplasms (IPMN), 2 adenocarcinomas, 1 low-grad

48 e origin of pancreatic intraductal papillary mucinous neoplasms (IPMN).

49 ignant mucinous cysts (intraductal papillary mucinous neoplasm [IPMN], mucinous cystic neoplasm [MCN]

50 ations are reported in intraductal papillary mucinous neoplasms (IPMNs) and in McCune-Albright syndro

51 AC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their patho

52 Intraductal papillary mucinous neoplasms (IPMNs) are the most frequent cystic

53 iagnostic criterion of intraductal papillary mucinous neoplasms (IPMNs) involving the main duct (MD I

54 e growing awareness of intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas among clinici

55 Intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas are ideal neo

56 radiographic imaging, Intraductal Papillary Mucinous Neoplasms (IPMNs) of the pancreas are identifie

57 Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas arising in br

58 molecular pathology of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas has not been

59 Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas have been sug

60 ed in association with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.

61 s cystadenomas (SCAs), intraductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms (M

62 elines for branch-duct intraductal papillary mucinous neoplasms (IPMNs).

63 If the mucinous neoplasm is minimally invasive and cytoreductio

64 Pancreatic cysts may be intraductal mucinous neoplasms, mucinous cystic neoplasms, serous cy

65 stic neoplasms (n=17), intraductal papillary mucinous neoplasms (n=15), serous cystadenomas (n=12), o

66 Mucinous neoplasms of the appendix were found in 5 of 17

67 carcinomas arising in intraductal papillary mucinous neoplasms of the pancreas (IPMN) by histologica

68 Intraductal papillary mucinous neoplasms of the pancreas are being recognized

69 Current understanding is that all cystic mucinous neoplasms of the pancreas are potentially malig

70 f 84 patients (70 women, 14 men) with cystic mucinous neoplasms of the pancreas, 54 were classified a

71 Mucinous (intraductal mucinous neoplasm or mucinous cystic neoplasm) lesions h

72 esions (ie, high-grade intraductal papillary mucinous neoplasms or grade 3 pancreatic intraepithelial

73 Intraductal papillary mucinous neoplasm (particularly the branch duct variant)

74 Intraductal papillary mucinous neoplasm patients appear to have cancer risk in

75 (4/58, 6.9%) than non- intraductal papillary mucinous neoplasms PDAC (5/385, 1.3%) (P = .02).

76 In invasive intraductal papillary mucinous neoplasm, recurrence was similar after partial

77 Invasive intraductal papillary mucinous neoplasm recurs frequently even after a complet

78 contrast, noninvasive intraductal papillary mucinous neoplasm recurs infrequently after resection, a

79 a larger proportion of intraductal papillary mucinous neoplasms-related tumors (4/58, 6.9%) than non-

80 itonei (PMP) originating from an appendiceal mucinous neoplasm remains a biologically heterogeneous d

81 Intraductal papillary mucinous neoplasms represent a distinct clinicopathologi

82 s of the treatment of intraductal pancreatic mucinous neoplasms shed some light on the management of

83 Appendiceal mucinous neoplasms sometimes present with peritoneal dis

84 Smad4 both regulate an intraductal papillary mucinous neoplasm-to-PDAC sequence through distinct tumo

85 ative R0 microinvasive intraductal papillary mucinous neoplasms (without recurrence at 27, 29, and 34